IN-ACTIV: NRx tanks as peptide fails NIH trial in severe COVID-19 patients
IN-ACTIV: NRx tanks as peptide fails NIH trial in severe [...]
Forte fields demand to liquidate from top shareholder who says latest asset came ‘out of thin air’
Forte fields demand to liquidate from top shareholder who says [...]
With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech
With failed COVID shot still dragging on earnings, CureVac tries [...]
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
Antios rocked as hepatitis B safety signal sparks clinical hold, [...]
CSL Behring gene therapy makes comeback after hold for FDA priority review
CSL Behring gene therapy makes comeback after hold for FDA [...]
Genocea closes up shop after failing to find a buyer, delists from Nasdaq
Genocea closes up shop after failing to find a buyer, [...]
Manufacturing concerns sideline INmune’s US Alzheimer’s trial
Manufacturing concerns sideline INmune’s US Alzheimer’s trial aarmstrong Tue, 05/24/2022 [...]
Moderna tunes vaccine platform to next potential viral threat: monkeypox
Moderna tunes vaccine platform to next potential viral threat: monkeypox [...]
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin out preps FDA filing
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin [...]
Biohaven flunks first clinical test for rare disease drug post-Pfizer sell-off
Biohaven flunks first clinical test for rare disease drug post-Pfizer [...]